. . . "For example, forward-looking statements include statements regarding our plan to initiate a Phase IIb MDX clinical trial for the treatment of Fragile X Syndrome, timing of commencement of such trials, the design and other aspects thereof, the potential of MDX to treat cognitive symptoms and the potential of such clinical trial to provide insight into the potential role of MDX in Fragile X Syndrome" .